<p>细胞动力（NASDAQ:CYTK - 获取免费报告）于周四公布了季度财报。这家生物制药公司报告本季度每股收益为（$1.12），超出分析师一致预期的（$1.34）$0.22，Zacks 报道。该公司本季度的收入为 6677 万美元，而一致预期为 195 万美元。去年同期，该公司的每股收益为（$1.31）。与去年同期相比，该公司的季度收入增长了 26727.3%。</p>
<h2>细胞动力价格表现</h2>
<ul>
<li>分析师认为现在仍然有机会投资 Edgewise，股价上涨 332%</li>
</ul>
<p>NASDAQ:CYTK 在周五的交易时段下跌了$1.14，报$34.11。该公司交易了 2,104,845 股，较其平均交易量 1,250,101 股有所增加。该公司的市值为 40.7 亿美元，市盈率为-6.69，贝塔值为 0.64。细胞动力的 52 周低点为$29.31，52 周高点为$59.39。该公司的 50 日移动平均价格为$34.88，200 日移动平均价格为$38.76。</p>
<h2>细胞动力内部交易活动</h2>
<p>在其他细胞动力的新闻中，董事 Edward M. Md Kaye 于 6 月 5 日星期四出售了 3,636 股公司的股票。股票以平均价格$32.10 出售，总交易额为$116,715.60。出售后，该董事持有 29,658 股公司的股票，估值约为$952,021.80。此次交易使其持股减少了 10.92%。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。此外，执行副总裁 Fady Ibraham Malik 于 8 月 5 日星期二出售了 2,000 股公司的股票。股票以平均价格$36.34 出售，总交易额为$72,680.00。出售后，该执行副总裁直接持有公司 140,610 股，估值约为$5,109,767.40。这代表其持股减少了 1.40%。该销售的披露信息可在此处找到。过去 90 天内，内部人士已出售 39,749 股公司股票，价值$1,350,617。内部人士持有 2.70% 的股票。</p>
<h2>细胞动力的机构交易</h2>
<ul>
<li>想要在生物技术领域获得多元化的上行潜力？查看 LABU</li>
</ul>
<p>一家对冲基金最近增加了对细胞动力股票的持股。Cetera Investment Advisers 在第二季度将其在细胞动力公司的股份提高了 12.4%，根据该公司最近向证券交易委员会提交的 13F 文件。该公司在此期间增持了 731 股，持有 6,635 股生物制药公司的股票。Cetera Investment Advisers 在细胞动力的持股在最近一个季度末价值为$219,000。</p>
<h2>分析师评级变动</h2>
<p>多家券商最近对 CYTK 进行了评估。Raymond James Financial 于 7 月 30 日星期三开始覆盖细胞动力的股票。他们对该公司设定了 “市场表现” 评级。瑞穗证券将细胞动力的目标价格从$103.00 下调至$84.00，并在 5 月 29 日星期四的研究报告中对该股票设定了 “跑赢大盘” 评级。花旗集团将细胞动力的目标价格从$80.00 下调至$77.00，并在周五的研究报告中对该股票设定了 “买入” 评级。瑞银集团将细胞动力的目标价格从$47.00 下调至$41.00，并在 5 月 2 日星期五的研究报告中对该股票设定了 “中性” 评级。最后，美国银行将细胞动力的目标价格从$62.00 下调至$54.00，并在 4 月 15 日星期二的研究报告中对该股票设定了 “中性” 评级。四位股票研究分析师对该股票给予了持有评级，十位给予了买入评级，两位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价格为$70.69。</p>
<p><strong>阅读我们对细胞动力的最新分析</strong></p>
<h2>关于细胞动力</h2>
<p>（获取免费报告）</p>
<p>细胞动力公司是一家处于后期阶段的生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为潜在的治疗虚弱疾病的方案。该公司主要开发小分子药物候选者，旨在影响肌肉功能和收缩性。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过细胞动力</li>
<li>CD 计算器：定期存款计算器</li>
<li>Rocket Lab 报告第二季度业绩：牛市论点是否仍然成立？</li>
<li>投资于高市盈率成长股</li>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
<li>道琼斯策略是什么？概述和示例</li>
<li>现在是购买 Cheniere Energy 的好时机：预计将创下新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在细胞动力吗？</h2>
<p>在考虑细胞动力之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而细胞动力并不在名单上。</p>
<p>虽然细胞动力目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

细胞动力

<p>细胞动力（NASDAQ:CYTK）报告季度每股收益为（$1.12），超出预期的（$1.34）$0.22。公司实现收入 6677 万美元，显著超过 195 万美元的预测，同比增长 26727.3%。股票交易下跌至 34.11 美元，市值为 40.7 亿美元。内部交易活动包括董事 Edward M. Md Kaye 和执行副总裁 Fady Ibraham Malik 的销售。分析师评级显示共识为 “适度买入”，平均目标价为 70.69 美元</p>

<p>Cytokinetics (NASDAQ:CYTK - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating analysts' consensus estimates of ($1.34) by $0.22, Zacks reports. The company had revenue of $66.77 million for the quarter, compared to the consensus estimate of $1.95 million. During the same quarter in the previous year, the business earned ($1.31) EPS. The company's quarterly revenue was up 26727.3% compared to the same quarter last year.</p>
<div class="lb-trans"><p>细胞动力（NASDAQ:CYTK - 获取免费报告）于周四公布了季度财报。这家生物制药公司报告本季度每股收益为（$1.12），超出分析师一致预期的（$1.34）$0.22，Zacks 报道。该公司本季度的收入为 6677 万美元，而一致预期为 195 万美元。去年同期，该公司的每股收益为（$1.31）。与去年同期相比，该公司的季度收入增长了 26727.3%。</p>
</div><h2>Cytokinetics Price Performance</h2>
<div class="lb-trans"><h2>细胞动力价格表现</h2>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为现在仍然有机会投资 Edgewise，股价上涨 332%</li>
</ul>
</div><p>NASDAQ:CYTK traded down $1.14 during trading hours on Friday, hitting $34.11. 2,104,845 shares of the company were exchanged, compared to its average volume of 1,250,101. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -6.69 and a beta of 0.64. Cytokinetics has a 52-week low of $29.31 and a 52-week high of $59.39. The company's 50 day moving average price is $34.88 and its 200-day moving average price is $38.76.</p>
<div class="lb-trans"><p>NASDAQ:CYTK 在周五的交易时段下跌了$1.14，报$34.11。该公司交易了 2,104,845 股，较其平均交易量 1,250,101 股有所增加。该公司的市值为 40.7 亿美元，市盈率为-6.69，贝塔值为 0.64。细胞动力的 52 周低点为$29.31，52 周高点为$59.39。该公司的 50 日移动平均价格为$34.88，200 日移动平均价格为$38.76。</p>
</div><h2>Insider Activity at Cytokinetics</h2>
<div class="lb-trans"><h2>细胞动力内部交易活动</h2>
</div><p>In other Cytokinetics news, Director Edward M. Md Kaye sold 3,636 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $32.10, for a total transaction of $116,715.60. Following the sale, the director owned 29,658 shares of the company's stock, valued at approximately $952,021.80. The trade was a 10.92% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $36.34, for a total transaction of $72,680.00. Following the sale, the executive vice president directly owned 140,610 shares in the company, valued at approximately $5,109,767.40. This represents a 1.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,749 shares of company stock worth $1,350,617 in the last 90 days. 2.70% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他细胞动力的新闻中，董事 Edward M. Md Kaye 于 6 月 5 日星期四出售了 3,636 股公司的股票。股票以平均价格$32.10 出售，总交易额为$116,715.60。出售后，该董事持有 29,658 股公司的股票，估值约为$952,021.80。此次交易使其持股减少了 10.92%。该交易已在提交给证券交易委员会的文件中披露，文件可在此链接查看。此外，执行副总裁 Fady Ibraham Malik 于 8 月 5 日星期二出售了 2,000 股公司的股票。股票以平均价格$36.34 出售，总交易额为$72,680.00。出售后，该执行副总裁直接持有公司 140,610 股，估值约为$5,109,767.40。这代表其持股减少了 1.40%。该销售的披露信息可在此处找到。过去 90 天内，内部人士已出售 39,749 股公司股票，价值$1,350,617。内部人士持有 2.70% 的股票。</p>
</div><h2>Institutional Trading of Cytokinetics</h2>
<div class="lb-trans"><h2>细胞动力的机构交易</h2>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上行潜力？查看 LABU</li>
</ul>
</div><p>A hedge fund recently raised its stake in Cytokinetics stock. Cetera Investment Advisers raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 12.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,635 shares of the biopharmaceutical company's stock after acquiring an additional 731 shares during the period. Cetera Investment Advisers' holdings in Cytokinetics were worth $219,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对细胞动力股票的持股。Cetera Investment Advisers 在第二季度将其在细胞动力公司的股份提高了 12.4%，根据该公司最近向证券交易委员会提交的 13F 文件。该公司在此期间增持了 731 股，持有 6,635 股生物制药公司的股票。Cetera Investment Advisers 在细胞动力的持股在最近一个季度末价值为$219,000。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages recently weighed in on CYTK. Raymond James Financial began coverage on shares of Cytokinetics in a report on Wednesday, July 30th. They set a &#34;market perform&#34; rating for the company. Mizuho cut their target price on shares of Cytokinetics from $103.00 to $84.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, May 29th. Citigroup cut their target price on shares of Cytokinetics from $80.00 to $77.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday. UBS Group cut their target price on shares of Cytokinetics from $47.00 to $41.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, May 2nd. Finally, Bank of America cut their target price on shares of Cytokinetics from $62.00 to $54.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday, April 15th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $70.69.</p>
<div class="lb-trans"><p>多家券商最近对 CYTK 进行了评估。Raymond James Financial 于 7 月 30 日星期三开始覆盖细胞动力的股票。他们对该公司设定了 “市场表现” 评级。瑞穗证券将细胞动力的目标价格从$103.00 下调至$84.00，并在 5 月 29 日星期四的研究报告中对该股票设定了 “跑赢大盘” 评级。花旗集团将细胞动力的目标价格从$80.00 下调至$77.00，并在周五的研究报告中对该股票设定了 “买入” 评级。瑞银集团将细胞动力的目标价格从$47.00 下调至$41.00，并在 5 月 2 日星期五的研究报告中对该股票设定了 “中性” 评级。最后，美国银行将细胞动力的目标价格从$62.00 下调至$54.00，并在 4 月 15 日星期二的研究报告中对该股票设定了 “中性” 评级。四位股票研究分析师对该股票给予了持有评级，十位给予了买入评级，两位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价格为$70.69。</p>
</div><p><strong>Read Our Latest Analysis on Cytokinetics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对细胞动力的最新分析</strong></p>
</div><h2>About Cytokinetics</h2>
<div class="lb-trans"><h2>关于细胞动力</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p>
<div class="lb-trans"><p>细胞动力公司是一家处于后期阶段的生物制药公司，专注于发现、开发和商业化肌肉激活剂和抑制剂，作为潜在的治疗虚弱疾病的方案。该公司主要开发小分子药物候选者，旨在影响肌肉功能和收缩性。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Cytokinetics</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Now Is a Great Time to Buy Cheniere Energy: New High Expected</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过细胞动力</li>
<li>CD 计算器：定期存款计算器</li>
<li>Rocket Lab 报告第二季度业绩：牛市论点是否仍然成立？</li>
<li>投资于高市盈率成长股</li>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来</li>
<li>道琼斯策略是什么？概述和示例</li>
<li>现在是购买 Cheniere Energy 的好时机：预计将创下新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CYTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在细胞动力吗？</h2>
</div><p>Before you consider Cytokinetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑细胞动力之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而细胞动力并不在名单上。</p>
</div><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然细胞动力目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

细胞动力（NASDAQ:CYTK）公布了财报结果，每股收益超出预期 0.22 美元